Alebund completes enrollment in Phase III AP301 trial: full analysis
Version 2
Alebund Pharmaceuticals has finished enrolling patients in RESPOND-2, a global Phase III pivotal trial testing AP301 for hyperphosphatemia in chronic kidney disease patients receiving maintenance dialysis. The announcement, made May 6, 2026, marks an operational milestone for a program Alebund is positioning as a next-generation phosphate binder with potential use in major markets including the U.S. and China. (prnewswire.com)
Hyperphosphatemia is a longstanding problem in dialysis care, and it’s been difficult to manage consistently in real-world practice. Existing phosphate binders can work, but adherence is often undermined by gastrointestinal side effects and a high pill burden, a challenge Alebund has repeatedly highlighted in prior AP301 updates. That backdrop helps explain why the company has continued to advance AP301 through multiple late-stage studies rather than relying on a single regional dataset. (en.prnasia.com)
According to ClinicalTrials.gov, RESPOND-2 is a randomized, double-blind, multi-regional Phase III study designed to evaluate the efficacy and safety of AP301 on serum phosphorus control in chronic kidney disease patients on maintenance dialysis with hyperphosphatemia. Alebund’s press release identifies the study as AP301-HP-03 and says enrollment is now complete, though the company did not disclose patient totals in the release excerpt surfaced by search. The trial follows RESPOND-1, a separate Phase III pivotal study in Chinese dialysis patients, which Alebund said produced positive topline results in 2025 and was later presented at the ASN 2025 Congress. (clinicaltrials.gov)
The company is describing AP301 as a novel fiber-iron-based phosphate binder, and earlier company statements have emphasized the prospect of reduced pill burden, good tolerability, and improved compliance. Those claims should still be viewed through the lens of pending full global Phase III data, but they point to the commercial and clinical case Alebund is trying to build in a crowded phosphate-control market. Competitors and adjacent therapies, including tenapanor and other phosphate-lowering approaches, have kept pressure on developers to show not just biochemical efficacy, but also practical advantages for long-term use. (en.prnasia.com)
Independent expert reaction to this specific enrollment update was limited in publicly available sources at the time of writing. Still, industry coverage framed the event as a meaningful de-risking step for the AP301 program because enrollment completion usually signals that the study is moving from recruitment execution to follow-up, data cleaning, and eventual readout. Alebund’s own prior comments around RESPOND-1 suggest the company is already thinking ahead to regulatory strategy, at least in China, where it said it was engaging with the National Medical Products Administration on an AP301 new drug application plan. (clinicaltrialsarena.com)
Why it matters: For veterinary professionals, this is less about immediate clinical relevance and more about translational awareness. Kidney disease management in companion animals also centers on phosphorus control, diet, and binder use, so developments in the human nephrology pipeline can offer useful signals about where formulation science, adherence-focused design, and mineral-bone disorder management are heading. It’s also a reminder that industry investment remains strong in renal supportive care, not just in disease-modifying therapies. (prnewswire.com)
What to watch: The key next steps are completion of treatment and follow-up in RESPOND-2, disclosure of topline efficacy and safety results, and any indication that Alebund will pursue regulatory submissions in the U.S., China, or other markets based on the combined Phase III package. (prnewswire.com)